Sign In
Buy PFE
$25.36
-0.200 (-0.783%)
At Close: Jun 03, 2026
Arrow Capital Pty Ltd Has $6.37 Million Holdings in Pfizer Inc. $PFE
04:18am, Sunday, 15'th Mar 2026
Arrow Capital Pty Ltd raised its stake in shares of Pfizer Inc. (NYSE: PFE) by 30.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institut
44 Wealth Management LLC Buys Shares of 24,551 Pfizer Inc. $PFE
03:22am, Sunday, 15'th Mar 2026
44 Wealth Management LLC bought a new position in Pfizer Inc. (NYSE: PFE) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission.
4 'Safer' Dividend Buys In Barron's 23 Better March Bets Than T-Bills
04:30am, Saturday, 14'th Mar 2026
Verizon, KeyCorp, Regions Financial, and Kinder Morgan currently meet the 'dogcatcher' ideal, with dividends from $1,000 invested exceeding their share prices. Analyst projections suggest top-ten Barr
Game Creek Capital LP Trims Stake in Pfizer Inc. $PFE
03:50am, Saturday, 14'th Mar 2026
Game Creek Capital LP cut its holdings in Pfizer Inc. (NYSE: PFE) by 23.9% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The f
Expect Pfizer To Comeback: Take The Dividend While Waiting For Capital Appreciation
05:01pm, Friday, 13'th Mar 2026
Pfizer Inc. (PFE) is undervalued at 8–9× forward earnings, offering a nearly 7% dividend yield and significant upside potential. Recent acquisitions, especially Seagen, position PFE for robust grow
1 Magnificent Dividend Stock Down 57% to Buy and Hold Forever
04:50am, Friday, 13'th Mar 2026
Pfizer has been hurt in recent years after the COVID-19 pandemic and recent drug pricing pressure. The stock now trades at a dividend yield of 6.5%.
Pfizer (PFE) Sees a More Significant Dip Than Broader Market: Some Facts to Know
06:46pm, Thursday, 12'th Mar 2026
Pfizer (PFE) closed the most recent trading day at $26.86, moving 1.61% from the previous trading session.
Capital World Investors Purchases 286,493 Shares of Pfizer Inc. $PFE
04:08am, Thursday, 12'th Mar 2026
Capital World Investors lifted its position in shares of Pfizer Inc. (NYSE: PFE) by 2.1% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities a
Why BridgeBio Leapfrogged Its 50-Day Line On Pfizer's Patent Shake-Up
02:34pm, Tuesday, 10'th Mar 2026
BridgeBio stock popped Tuesday on a notable shake-up in the patent battle surrounding Pfizer's rival drug, tafamidis.
2 Healthcare Stocks That Are Too Cheap to Ignore
12:23pm, Tuesday, 10'th Mar 2026
Pfizer and Novo Nordisk are trading at (more than) reasonable levels given their underlying strengths. Both drugmakers could make pipeline progress that will allow them to improve their financial resu
FDA Approves Leucovorin—But Not For Autism, Even After Trump Admin Officials Touted Drug Last Year
11:05am, Tuesday, 10'th Mar 2026
The Food and Drug Administration approved the drug leucovorin as a treatment for the rare genetic condition cerebral folate deficiency on Tuesday—but stopped short of approving it as a treatment
3 Healthcare Stocks Paying the Highest Dividends of 2026
08:45am, Tuesday, 10'th Mar 2026
A handful of the industry's income-generating gems are hiding in plain sight.
Pfizer's Payout Ratio Is Still Over 100%. Is a Dividend Cut Inevitable?
02:00pm, Monday, 09'th Mar 2026
Pfizer's per-share profit in 2025 declined as the company incurred significant impairment charges. The company also paid out more in dividends than it generated in free cash flow.
2 Top AI Healthcare Stocks to Buy and Hold
11:00am, Monday, 09'th Mar 2026
Pfizer and Eli Lilly are both actively using artificial intelligence to improve their businesses. While these efforts are noteworthy, there are still better reasons to invest in the two stocks.
Roche Shares Drop Up to 7.5% After Breast Cancer Pill Misses Trial Goal
09:21am, Monday, 09'th Mar 2026
Roche (RHHBY) shares came under pressure in early Zurich trading after the Swiss drugmaker reported that its experimental breast-cancer pill giredestrant failed
